About Us
Conigen Bioscience, Inc., based in Worcester, Massachusetts, is a science-driven life science tools company that integrates state-of-the-art immunology, virology, molecular biology and cell biology to create new bioactive advanced protein reagents, high-quality assays and bioengineering services, for a broad range of novel targets to enable new drug modalities, from discovery to development to manufacturing.
Conigen was founded to bridge a critical gap in therapeutic antibody and drug discovery – addressing the limited availability of recombinant proteins that accurately represent native conformational epitopes. With proprietary protein platforms, we engineer conformational immunogens and antigens that mimic native conformational epitopes, in membrane associated and soluble forms. We provide high quality protein products that serve as essential tools to advance precision antibody discovery.
The Conigen team's expertise
Our team, a cohesive group of innovative scientists, embodies a start-up spirit with extensive experience and expertise in developing scientific tools. Our rigorous scientific methodology, combined with expertise in rational protein design, fosters a creative pursuit of solutions leading to the highest-quality antigens and immunogens.
Novel immunogens for viral proteins, bacterial proteins, immune oncology targets, GPCRs, cytokine receptors and other molecules developed
Peer-reviewed publications in vaccinology, immunology and protein engineering
This shared commitment drives us to redefine the landscape of engineered protein tools and immunogens, paving the way for groundbreaking advancements in therapeutic discoveries, making the unseen seen and the impossible possible.
Leadership
Jean Qiu, PhD
Chief Executive Officer and Co-Founder
Dr. Qiu was the Founder & Chief Technology Officer of Nexcelom Bioscience. From the basement of her home, she started Nexcelom in 2003, with the goal of automating manual cell counting on the biologist’s lab bench using image cytometry technologies. This product portfolio was expanded to include cell counting and cell-based assay instruments, software, consumables and reagent kits, which are distributed globally. Nexcelom was acquired by PerkinElmer in 2021. Dr. Qiu has published over 50 papers in peer-reviewed academic journals and holds more than 35 patents.
Shixia Wang, PhD, DVM
Chief Scientific Officer and Co-Founder
Dr. Wang was a professor at the University of Massachusetts Chan Medical School, focused on vaccine and antibody research and discovery since 1996. In 2021, as the senior director of immunology in a vaccine company, she successfully enhanced the team and the department’s capabilities, and built a state-of-the-art immunology lab from scratch in record time. Dr. Wang has extensive knowledge and expertise in vaccinology, immunology, infectious diseases, virology, microbiology and antibody research. Her rich experiences cover immunogen design, modern immunological and virological assays, bioanalytical and GLP assay development and management, toxicology and clinical study design, process development for DNA and protein vaccine GMP manufacturing and PreIND/IND filing. Dr. Wang has published over 160 peer-reviewed papers and holds 12 patents.